Park Wookyung, Kim Mirinae, Kim Rae Young, Park Young-Hoon
Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2155-2161. doi: 10.1007/s00417-019-04426-8. Epub 2019 Jul 31.
To compare the effects of full-dose, half-dose, and half-dose-half-fluence photodynamic therapy (PDT) in central serous chorioretinopathy (CSC).
This retrospective study enrolled patients with CSC who received full-dose (verteporfin 6 mg/m), half-dose (verteporfin 3 mg/m), and half-dose-half-fluence (verteporfin 3 mg/m and light energy reduced to 25 J/cm) PDT. We measured visual acuity, subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) thickness, and choroidal vascularity index (CVI) before and 3 months after PDT.
Forty-three eyes (42 patients) were analyzed. Full-dose and half-dose groups showed improved vision (P = 0.023, 0.004, respectively), but half-dose-half-power group was not significantly improved (P = 0.254). SFCT in all three groups were significantly decreased (P = 0.005, 0.004, 0.002, respectively). SRF thicknesses in full-dose and half-dose groups showed significant decreases (P = 0.005, < 0.001, respectively). Half-dose-half-fluence group demonstrated the decrease but it was not statistically significant (P = 0.084). CVI were decreased in full-dose and half-dose groups (all P = 0.005). However, in the half-dose-half-fluence group, CVI was increased (P = 0.003).
Full-dose and half-dose PDT were both effective in CSC treatment. Half-dose PDT can be considered to reduce complications. The effect of half-dose-half-fluence PDT was less clear than the other two protocols.
比较全剂量、半剂量和半剂量-半光通量光动力疗法（PDT）治疗中心性浆液性脉络膜视网膜病变（CSC）的效果。
这项回顾性研究纳入了接受全剂量（维替泊芬6mg/m²）、半剂量（维替泊芬3mg/m²）和半剂量-半光通量（维替泊芬3mg/m²且光能降低至25J/cm²）PDT治疗的CSC患者。我们在PDT治疗前和治疗后3个月测量了视力、黄斑中心凹下脉络膜厚度（SFCT）、视网膜下液（SRF）厚度和脉络膜血管指数（CVI）。
分析了43只眼（42例患者）。全剂量组和半剂量组视力均有改善（P分别为0.023、0.004），但半剂量-半功率组视力改善不明显（P = 0.254）。三组的SFCT均显著降低（P分别为0.005、0.004、0.002）。全剂量组和半剂量组的SRF厚度均显著降低（P分别为0.005、<0.001）。半剂量-半光通量组SRF厚度有所降低，但差异无统计学意义（P = 0.084）。全剂量组和半剂量组的CVI均降低（所有P = 0.005）。然而，半剂量-半光通量组的CVI升高（P = 0.003）。
全剂量和半剂量PDT治疗CSC均有效。可考虑采用半剂量PDT以减少并发症。半剂量-半光通量PDT的效果不如其他两种方案明确。
